Molecular Templates Inc
NASDAQ:MTEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Molecular Templates Inc
Interest Expense
Molecular Templates Inc
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Templates Inc
NASDAQ:MTEM
|
Interest Expense
$139k
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Expense
$2.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Expense
$1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Expense
$2.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Expense
$13.3m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Expense
$43.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
12%
|
|
Molecular Templates Inc
Glance View
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 261 full-time employees. The company went IPO on 2005-02-04. The firm utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The firm is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.
See Also
What is Molecular Templates Inc's Interest Expense?
Interest Expense
139k
USD
Based on the financial report for Jun 30, 2024, Molecular Templates Inc's Interest Expense amounts to 139k USD.
What is Molecular Templates Inc's Interest Expense growth rate?
Interest Expense CAGR 5Y
-35%
Over the last year, the Interest Expense growth was -97%. The average annual Interest Expense growth rates for Molecular Templates Inc have been -61% over the past three years , -35% over the past five years .
